BioNTech received ﾀ375M in funding from German Federal Ministry to support COVID-19 vaccine program BNT162
On Sept. 15, 2020, BioNTech announced that had receive a grant of up to 375 million Euro from…
Biotechnology | COVID-19 | Infectious Disease | Influenza | NIH | Vaccine
Vaxess Technologies to develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen
On Sept. 15, 2020, Vaxess Technologies and Medigen Vaccine Biologics (MBV) announced a partnership to develop a combined…
Thermo Fisher Scientific further expanded laboratory plastics production to support COVID-19 testing, therapies and vaccines
On Sept. 15, 2020, Thermo Fisher Scientific announced it was investing more than $140 million to further expand…
Soligenix announced publication demonstrating thermostabilization of filovirus vaccine antigens
On Sept. 15, 2020, Soligenix announced publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and…
Flu may increase the spread of Covid-19
On Sept. 14, 2020, scientists at the Max Planck Institute for Infection Biology in Berlin and the Institut…
Valneva announced COVID-19 vaccine partnership with UK Government
On Sept. 14, 2020, Valneva announced a vaccine partnership with the UK government for its inactivated COVID-19 vaccine,…
Valneva and Dynavax announced commercial supply agreement for inactivated, adjuvanted COVID-19 vaccine
On Sept. 14, 2020, Dynavax Technologies announced a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant…
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
On Sept. 12 2020, Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK…
MediciNova announced intranasal RS virus vaccine vuccessfully induced neutralizing antibodies against RS virus in mice
On Sept. 11, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary paused
On Sept. 9, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
Sinovac reported preliminary phase I/II results of COVID-19 vaccine in elderly volunteers
On Sept. 9, 2020, Sinovac Biotech announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences…
The ACIP updated flu vaccine recommendations for 2020-2021
On Sept. 9, 2020, the American Academy of Family Physicians (AAFP) reviewed and agreed with the Advisory Committee…
Valneva announced IXIARO supply contract with the U.S. Government worth up to $166 million
On Sept. 9, 2020, Valneva announced the signing of a new contract, lasting up to three years, with…
Pfizer and BioNTech announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
Pfizer and BioNTech to potentially supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 9, 2020, Pfizer and BioNTech announced that they had submitted an amended protocol to the FDA…
BioNTech and Pfizer announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
iBio advanced COVID-19 LicKM-subunit vaccine candidate, IBIO-201
On Sept. 9, 2020, iBio announced that it had selected IBIO-201, its LicKMﾙ-ubunit vaccine, as its leading candidate…
Merck announced positive topline results from phase 3 adult studies evaluating investigational 15-valent pneumococcal conjugate vaccine
On Sept. 9, 2020, Merck announced announced that two Phase 3 studies evaluating the safety, tolerability and immunogenicity…
Biopharma leaders united to stand with science
On Sept. 8, 2020, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and…
Vaxartﾒs oral COVID-19 vaccine candidate induced potent systemic and mucosal immune responses in preclinical studies
On Sept. 8, 2020, Vaxart announced pre-publication of a manuscript titled ﾓPreclinical studies of a recombinant adenoviral mucosal…
INOVIO added Thermo Fisher Scientific to global manufacturing consortium
On Sept. 8, 2020, INOVIO announced that Thermo Fisher Scientific, the world leader in serving science, had signed…
BioNTech and Pfizer receive regulatory approval to commence global phase 2/3 trial for COVID-19 vaccine candidate
On Sept. 7, 2020, Pfizer and BioNTech announced that the German regulatory authority, the Paul-Ehrlich-Institut, had approved the…
US Departments of HHS and DoD announced collaboration with McKesson for COVID-19 vaccine distribution
On Sept. 4, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD),…
CureVac expected to receive up to 252 million Euros from German Federal Ministry of Research for further COVID-19 vaccine development
On Sept. 4, 2020, CureVac announced that it had received notification from the German Federal Ministry of Education…
Johnson & Johnson announced COVID-19 investigational vaccine candidate prevents severe clinical disease in hamsters
On Sept. 3, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
U.S. Department of Defense sites selected for phase III COVID-19 vaccine trials
On Sept. 3, 2020, the U.S Department of Defense announced that five locations were identified to participate in…
Sanofi and GSK initiated Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
On Sept. 3, 2020, Sanofi and GSK announced the start of the Phase 1/2 clinical trial for their…
COVID-19 vaccine study shows severe disease preventable in hamsters
On Sept. 3, 2020, Oregon Health & Science University (OHSU) announced that for the first time, early research…
RedHill Biopharma’s Opaganib awarded COVID-19 grant by State of Pennsylvania
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…
Novavax announced publication of phase 1 data for COVID-19 vaccine candidate in The New England Journal of Medicine
On Sept. 2, 2020, Novavax announced the publication in The New England Journal of Medicine of Phase 1…